Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

(marketscreener.com) CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of latent TGFβ selectively within the tumor microenvironmentCRB-601 significantly inhibits tumor growth as a single agent and enhances the efficacy of anti-PD-1 immunotherapy in checkpoint inhibitor sensitive and...https://www.marketscreener.com/quote/stock/CORBUS-PHARMACEUTICALS-HO-21683508/news/Corbus-Presents-Latest-Preclinical-Data-for-CRB-601-at-the-Society-for-Immunotherapy-of-Cancer-SITC-42271661/?utm_medium=RSS&utm_content=20221110